# OnCo record nct07581002 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct07581002/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct07581002", "NCT07581002" ;
  schema:name "A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)"@en ;
  schema:alternateName "REVIVAL"@en ;
  schema:description "A phase 2/3 trial of Pivekimab sunirine, Venetoclax and Azacitidine in acute myeloid leukaemia, run by AbbVie, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct07581002/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT07581002> ;
  onco:status "recruiting" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "2/3" ;
  schema:startDate "2026-06-30" ;
  onco:cancers <https://onco.cc/cancers/aml/> ;
  onco:technologies <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/bcl2-inhibitors/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/epigenetic-drugs/>, <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/pivekimab-sunirine/>, <https://onco.cc/drugs/venetoclax/>, <https://onco.cc/drugs/azacitidine/> ;
  onco:companies <https://onco.cc/companies/abbvie/> .